Mick Hurrey
Vice President, Product Development
InCarda Therapeutics
Mick has more than 17 years of pharmaceutical and device development experience within large multi-national biotechs to small innovative start-ups. His projects have ranged from solid oral dosage forms to computer controlled parenteral combination products across antiviral, oncology, and cardiopulmonary indications. Prior to joining InCarda, he served as the Senior Director of Pharmaceutical Development at SteadyMed Therapeutics working to launch a drug/device combination therapy for pulmonary arterial hypertension. Prior to SteadyMed, Mick worked at both Gilead Sciences and Vertex Pharmaceuticals helping to launch Harvoni®, Kalydeco®, and Incivek.
Mick earned his B.S. in Chemistry from the University of Central Florida and a Ph.D. in Analytical Chemistry from the University of North Carolina – Chapel Hill. Over his career, Mick has earned numerous awards for outstanding contributions both at his employer and for external organizations such as the ACS and IUPAC.